Last reviewed · How we verify

Iodophor 0.7% and IPA 74% w/w

Johns Hopkins University · FDA-approved active Small molecule

Iodophor 0.7% and IPA 74% w/w is a Topical antiseptic/disinfectant Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved for Skin antisepsis and disinfection, Preoperative skin preparation, Wound disinfection. Also known as: Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA).

This topical antiseptic formulation kills microorganisms through the antimicrobial action of iodine complexed with a carrier molecule, combined with the rapid bactericidal and virucidal effects of isopropyl alcohol.

This topical antiseptic formulation kills microorganisms through the oxidative and protein-denaturing properties of iodine combined with the rapid antimicrobial action of isopropyl alcohol. Used for Skin antisepsis and disinfection prior to medical procedures, Wound cleansing and antisepsis.

At a glance

Generic nameIodophor 0.7% and IPA 74% w/w
Also known asDuraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA)
SponsorJohns Hopkins University
Drug classTopical antiseptic/disinfectant
ModalitySmall molecule
Therapeutic areaInfection Prevention / Dermatology
PhaseFDA-approved

Mechanism of action

Iodophors are iodine-based complexes that release free iodine, which denatures proteins and disrupts microbial cell membranes and nucleic acids. The 74% isopropyl alcohol component provides rapid surface disinfection and evaporative drying. Together, they provide broad-spectrum antimicrobial coverage against bacteria, viruses, fungi, and spores, making this suitable for skin antisepsis and disinfection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Iodophor 0.7% and IPA 74% w/w

What is Iodophor 0.7% and IPA 74% w/w?

Iodophor 0.7% and IPA 74% w/w is a Topical antiseptic/disinfectant drug developed by Johns Hopkins University, indicated for Skin antisepsis and disinfection, Preoperative skin preparation, Wound disinfection.

How does Iodophor 0.7% and IPA 74% w/w work?

This topical antiseptic formulation kills microorganisms through the antimicrobial action of iodine complexed with a carrier molecule, combined with the rapid bactericidal and virucidal effects of isopropyl alcohol.

What is Iodophor 0.7% and IPA 74% w/w used for?

Iodophor 0.7% and IPA 74% w/w is indicated for Skin antisepsis and disinfection, Preoperative skin preparation, Wound disinfection.

Who makes Iodophor 0.7% and IPA 74% w/w?

Iodophor 0.7% and IPA 74% w/w is developed and marketed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).

Is Iodophor 0.7% and IPA 74% w/w also known as anything else?

Iodophor 0.7% and IPA 74% w/w is also known as Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA).

What drug class is Iodophor 0.7% and IPA 74% w/w in?

Iodophor 0.7% and IPA 74% w/w belongs to the Topical antiseptic/disinfectant class. See all Topical antiseptic/disinfectant drugs at /class/topical-antiseptic-disinfectant.

What development phase is Iodophor 0.7% and IPA 74% w/w in?

Iodophor 0.7% and IPA 74% w/w is FDA-approved (marketed).

What are the side effects of Iodophor 0.7% and IPA 74% w/w?

Common side effects of Iodophor 0.7% and IPA 74% w/w include Skin irritation, Allergic contact dermatitis (iodine sensitivity), Drying of skin.

Related